Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

NCT07287917 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma (Skin Cancer)
HER2-low Hormone Receptor Positive Breast Cancer

Interventions

DRUG: AMXT 1501 Dicaprate
DRUG: DFMO
DRUG: Fulvestrant
DRUG: Capivasertib
DRUG: Pembrolizumab

Sponsor

Aminex Therapeutics, Inc.